Technical Strategy and Investment Due Diligence from Discovery to IND
Moving an asset from early-stage discovery to an IND filing requires an uncommon blend of deep bench science, international regulatory foresight, and institutional investment strategy.
As a Molecular Biologist and Corporate Strategist holding a Ph.D. in Cellular and Molecular Biology, I specialize in bridging the gap between cutting-edge laboratory data and the rigorous demands of institutional investors and CDMO partners.
My career began with foundational research in Synthetic Biology. Having spent years running complex technical workflows on the ground, I bring real-world, hands-on experience to drug development. At EvolBio Limited, I leverage this background to guide early-stage innovators through technical de-risking, cross-border regulatory frameworks, and fundraising execution.
Over $1M+ in B2B Contracts Secured & Complex IP Portfolios Managed
Throughout my career, I have successfully transitioned complex biologics programs from early discovery through to IND submission readiness. My core focus is accelerating asset development timelines while simultaneously protecting investor capital. I ensure preclinical pipelines possess clear, scalable, and fully compliant pathways to both Western and Asian markets.
Scientific Strategy & De-Risking: Technical validation of preclinical data packages, molecule evaluation, and IND-readiness strategy for international developers.
APAC Market Entry & Hub Incubation: Guiding Western life science companies through regional corporate structuring, IP frameworks, and facilitating successful entry into premier Asian incubation hubs (such as HKSTP and Singapore frameworks).
Venture Capital Preparation: Translating complex biological milestones into structured, investor-ready pitch narratives to clear institutional due diligence.
IP Portfolio Management: Patent drafting strategy, asset defensibility, and cross-border technology transfer framework optimization.
Biologics CMC & Process De-Risking: Designing early-stage CMC strategies, evaluating cell lines, and optimizing scalable processes to ensure IND-ready preclinical batches.
Regulatory & cGMP Alignment: Ensuring technical platforms and preclinical developments comply strictly with international manufacturing and quality benchmarks.
Core Expertise
Ready to De-Risk Your Assets?
Submit the form or reach out directly to discuss how we can support your project milestones.